Volume 95 Issue 25 | p. 15 | Concentrates
Issue Date: June 19, 2017

WuXi Biologics shares surge on first day of trading

Department: Business
Keywords: finance, WuXi, IPO, biologics

Shares in WuXi Biologics surged 39% on June 13, its first day of trading on the Hong Kong Stock Exchange. The company, a Chinese contract researcher and manufacturer of antibody-drug conjugates and other biological drugs, raised more than $500 million from its initial public offering. WuXi Biologics is a subsidiary of the giant contract research firm WuXi AppTec, which delisted from the New York Stock Exchange in 2015 after a management buyout. At the time, WuXi’s Chair Ge Li said he did not intend to relist the company on a stock exchange in China.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment